ID
42549
Description
Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form has to be filled whenever/if additional scans have to be done during study.
Lien
https://clinicaltrials.gov/ct2/show/NCT00811733
Mots-clés
Versions (1)
- 25/08/21 25/08/21 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
25 agosto 2021
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733
Additional Scan
- StudyEvent: ODM
Description
Other protocol specified and/or additional scan
Alias
- UMLS CUI-1
- C2348563
- UMLS CUI-2
- C0011923
- UMLS CUI-3
- C0205394
- UMLS CUI-4
- C1524062
Description
Scan Method
Type de données
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C0871511
Description
Date of Scan
Type de données
date
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C0011008
Description
Anatomic location of image coverage
Type de données
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1515974
Description
Other anatomic location of image coverage
Type de données
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1515974
- UMLS CUI [1,3]
- C0205394
Description
Reminder: Any new lesions identified need to be indicated on the Response form and the details of the new lesions need to be entered onto the New Lesion form.
Type de données
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C3146298
Description
Reminder: Any new lesions identified need to be indicated on the Response form and the details of the new lesions need to be entered onto the New Lesion form.
Type de données
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205394
Description
If the result of the scan is unequivocal progression, ensure the Response Assessment form is completed.
Type de données
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1274040
Description
If the result of the scan is unequivocal progression, ensure the Response Assessment form is completed.
Type de données
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C1629507
Similar models
Additional Scan
- StudyEvent: ODM
C2985720 (UMLS CUI [2])
C0011923 (UMLS CUI-2)
C0205394 (UMLS CUI-3)
C1524062 (UMLS CUI-4)
C0011008 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C1629507 (UMLS CUI [1,3])
Aucun commentaire